Proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs. The company’s lead product (LEVADEX) is an orally inhaled migraine therapy.
In March 2013, MAP was acquired by Allergan (NYSE: AGN).
Investors 1
| Date | Name | Website |
| - | Bay City C... | baycitycap... |
Mentions in press and media 4
| Date | Title | Description | Category | Author | Source |
| 08.10.2007 | IPO roundu... | MAP Pharmaceuticals, the Mount... | - | - | venturebea... |
| 21.09.2007 | Life scien... | Featured companies: CG Therape... | - | - | venturebea... |
| 19.06.2007 | MAP Pharma... | MAP Pharmaceuticals, a Mountai... | - | - | venturebea... |
| 28.03.2007 | MAP Pharma... | MAP Pharmaceuticals, a Mountai... | - | - | venturebea... |